Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today shared initial clinical […]
TheraVet Optimizes its Commercial Strategy in France with a New Distribution Agreement with Elvetis
TheraVet, a pioneering biotechnology company in the treatment of bone and joint diseases in pets, […]
Kling Biotherapeutics Appoints Michael Koslowski, M.D. As Chief Executive Officer
Kling Biotherapeutics, a clinical-stage company pioneering the discovery and development of novel antibody-based therapeutics, today […]
SynAct Pharma to Make Strategic Acquisition of Swiss Biotech Company TXP Pharma
SynAct Pharma AB has announced that the company has entered into a conditional agreement on […]
HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery
Shanghai Stock Exchange-listed company HitGen has announced that it has entered into a research agreement […]
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
Erasca, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for […]
Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in Combination with Tislelizumab
Phanes Therapeutics, a clinical-stage biotech company focused on innovative drug discovery and development in oncology, […]
Vistin Pharma Enters into a Long-term Renewable Energy Supply Agreement with Statkraft
Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) announces that it has entered into a long-term […]
George Clinical to Accelerate International Growth Through Acquisition by Hillhouse
George Clinical announces that it has entered into a sale agreement with Hillhouse, a global […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more